

Industry Expanded Patient Assistance

Takeda Expands Patient Assistance in the U.S. During COVID-19 Crisis
April 22, 2020

To our valued patients, customers and other stakeholders,
As the COVID-19 crisis continues to unfold, Takeda's Patient Assistance Response team is working around the clock to help ensure that the people who need our medicines and treatments can continue to access them safely and without interruption.

Consistent with our commitment to prioritizing patients' needs, Takeda has enhanced its existing patient assistance programs for U.S. patients who qualify and need extra help during this difficult time. Highlights include:

- Implementing a new Job Loss Provision for Takeda's Help at Hand program and Takeda's Oncology Patient Support program to help eligible patients who have lost a job and are experiencing a financial hardship due to the COVID-19 pandemic. Click [here](#) for a listing of Takeda medicines available through the Takeda Help at Hand patient assistance and support program. Click [here](#) for Takeda's Oncology Patient Support Program.

- Enhancing free drug programs for eligible patients enrolled in Takeda's [OnePath](#), [Entyvio Connect](#), [Hematology Support Center](#), and [Takeda's Oncology Patient Support](#) programs, who have experienced a loss or gap in insurance coverage due to COVID-19;
- Extending the eligibility period for certain patients currently enrolled in Takeda's patient assistance programs to help reduce the time patients spend on securing medication approvals so they can focus on their health and safety during the pandemic;
- Implementing virtual training that pairs specially-trained nurses with patients to teach proper self-administration of certain Takeda medicines from the safety of patients' own homes. For more information, see contact information for Takeda's Patient Assistance Programs below.

Takeda's Patient Services Team is here to help you through this difficult time. For more information, as well as additional eligibility requirements, please refer to the following programs:

- For Takeda Help At Hand Patient Assistance Program (PAP), please call 1-800-830-9159, between 8:00am – 8:30pm ET, Monday through Friday
- For Entyvio Connect, please call 1-855-368-9846, between 8:00am –8:00pm ET, Monday through Friday
- For OnePath, please call 1-866-888-0660, between 8:30am – 8pm ET, Monday through Friday
- For Hematology Support Center, please call 1-888-229-8379, between 8:30am – 8pm ET, Monday through Friday
- For Takeda Oncology Patient Support, please call 1-844-817-6468, option 2, between 8:00am-8:00pm ET, Monday-Friday

Sincerely,

Daniel McNamara
Head of U.S. Patient Services

Dion Warren
Head of U.S. Oncology Business Unit

Industry Research and Trials

May 8, 2020 RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.

Read more [here](#)

April 15, 2020 Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine

Read more [here](#)

April 8, 2020 Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against COVID-19

Read more [here](#)

April 6, 2020 Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

Read more [here](#)

April 2, 2020 Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia

Read more [here](#)

March 4, 2020 Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19

Read more [here](#)